Trial to Compare the Safety, Tolerability, and Efficacy of Influenza Virus Vaccine, (CAIV-T) With Inactivated, Influenza Vaccine, Trivalent, Types A & B, in Adults Aged 60 Years and Older Against Culture-confirmed Influenza (FluMist)

This study has been completed.
Sponsor:
Collaborator:
Wyeth is now a wholly owned subsidiary of Pfizer
Information provided by:
MedImmune LLC
ClinicalTrials.gov Identifier:
NCT00192413
First received: September 13, 2005
Last updated: March 13, 2012
Last verified: March 2012
  Purpose

To demonstrate that the efficacy over a defined surveillance period against culture-confirmed influenza-illness caused by community-acquired subtypes antigenically similar to those contained in the vaccine, in adults aged at least 60 years at enrollment, of a single intranasally (IN) -administered dose of a liquid formulation of influenza virus vaccine,(CAIV-T) is non inferior compared with that of a single dose of commercially available influenza vaccine inactivated (TIV) administered intramuscularly (IM) prior to the anticipated commencement of the influenza season.


Condition Intervention Phase
Influenza
Biological: Cold-adapted influenza vaccine trivalent (CAIV-T)
Biological: Trivalent Inactivated Vaccine (TIV)
Phase 3

Study Type: Interventional
Study Design: Allocation: Randomized
Endpoint Classification: Safety/Efficacy Study
Intervention Model: Parallel Assignment
Masking: Open Label
Primary Purpose: Prevention
Official Title: A Prospective, Randomized, Open-Label, Controlled Trial to Compare the Safety, Tolerability, and Efficacy of Influenza Virus Vaccine, Trivalent, Types A & B, Live Cold-Adapted (CAIV-T) With Inactivated, Influenza Vaccine, Trivalent, Types A & B, in Adults Aged 60 Years and Older

Resource links provided by NLM:


Further study details as provided by MedImmune LLC:

Primary Outcome Measures:
  • The first episode of a culture-confirmed influenza-illness, caused by community-acquired subtypes antigenically similar to those contained in the vaccine, which occurs at least 15 days following receipt of a dose of study vaccine. [ Time Frame: Dosing through 30Nov2002 ] [ Designated as safety issue: No ]
    The criteria for obtaining nasal and throat swabs for viral culture were any one of the following: A feeling of "feverishness", An oral temperature ≥37.2ºC, Sore throat, New or increased cough, Malaise, Myalgia. Swabs for viral cultures were also obtained, if, in the opinion of the investigator, the symptom complex so warranted.


Secondary Outcome Measures:
  • The first episode of a culture-confirmed influenza-illness, caused by any community-acquired subtype, which occurs at least 15 days following receipt of a dose of study vaccine. [ Time Frame: 15 days after dosing through 30Nov2002 ] [ Designated as safety issue: No ]
    The criteria for obtaining nasal and throat swabs for viral culture were any one of the following: A feeling of "feverishness", An oral temperature ≥37.2ºC, Sore throat, New or increased cough, Malaise, Myalgia. Swabs for viral cultures were also obtained, if, in the opinion of the investigator, the symptom complex so warranted.

  • The first episode in a study subject of a culture-confirmed influenza illness caused by community-acquired virus of each of the subtypes antigenically similar to those contained in the vaccine [ Time Frame: 15 days after dosing through 30Nov2002 ] [ Designated as safety issue: No ]
    The criteria for obtaining nasal and throat swabs for viral culture were any one of the following: A feeling of "feverishness", An oral temperature ≥37.2ºC, Sore throat, New or increased cough, Malaise, Myalgia. Swabs for viral cultures were also obtained, if, in the opinion of the investigator, the symptom complex so warranted.

  • The first episode in a study subject of a culture-confirmed influenza illness caused by any community-acquired virus of each of the subtypes. [ Time Frame: 15 days after dosing through 30Nov2002 ] [ Designated as safety issue: No ]
    The criteria for obtaining nasal and throat swabs for viral culture were any one of the following: A feeling of "feverishness", An oral temperature ≥37.2ºC, Sore throat, New or increased cough, Malaise, Myalgia. Swabs for viral cultures were also obtained, if, in the opinion of the investigator, the symptom complex so warranted.

  • The first episode of influenza-like illness [ Time Frame: 15 days after dosing through 30Nov2002 ] [ Designated as safety issue: No ]
  • Incidence of clinic visits [ Time Frame: 15 days after dosing through 30Nov2002 ] [ Designated as safety issue: No ]
    A possibility of multiple visits per subject; each visit will be counted once in the analysis.

  • Incidence of hospitalization [ Time Frame: 15 days after dosing through 30Nov2002 ] [ Designated as safety issue: No ]
  • Incidence of confirmed pneumonia [ Time Frame: 15 days after dosing through 30Nov2002 ] [ Designated as safety issue: No ]
    Pneumonia means one or more areas of acute interstitial or alveolar infiltrates documented radiographically

  • Incidence of death due to influenza-like illness [ Time Frame: 15 days after dosing through 30Nov2002 ] [ Designated as safety issue: No ]
    With or without confirmation by viral culture or PCR analysis

  • Incidence of seroconversion [ Time Frame: Day 0-35 ] [ Designated as safety issue: No ]
    Seroconversion is defined as at least a 4-fold increase in titer from baseline to the sample 35 plus or minus 7 days after vaccination. all subjects were to provide serum samples at 2 time points: at study visit 1 prior to vaccination with CAIV-T or TIV, and 35 days ± 7 days following vaccination (study visit 2).

  • Incidence of systemic reactogenicity events [ Time Frame: Day 0-10 ] [ Designated as safety issue: Yes ]
    The 12 systemic reactions were fever with 3 grades defined as ≥37.2°C, ≥38.6°C, and ≥40°C based on the temperature reported on the diary card in addition to the 9 events reported on the diary card.

  • Incidence of local reactions [ Time Frame: Days 0-10 ] [ Designated as safety issue: Yes ]
    The local reactions were pain, redness (2 grades: any and significant), and swelling (also 2 grades).

  • Incidence of adverse events [ Time Frame: Days 0-10 ] [ Designated as safety issue: Yes ]

Enrollment: 3009
Study Start Date: March 2002
Study Completion Date: November 2002
Primary Completion Date: November 2002 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: Cold-adapted influenza vaccine trivalent (CAIV-T)
A single 0.2 mL dose of 10^7 fluorescent focus units was administered intranasally.
Biological: Cold-adapted influenza vaccine trivalent (CAIV-T)
Liquid CAIV-T vaccine for this study consisted of 3 cold-adapted, attenuated, reassortant strains, representing the HA and NA antigens of the A/New Caledonia/20/99 (H1N1), A/Panama/2007/99 (H3N2), and B/Victoria/504/2000 influenza strains. The vaccine contained no preservatives and had a pH of 7.2 ± 0.5.
Other Name: FluMist
Active Comparator: Trivalent Inactivated Vaccine (TIV)
A single dose was administered by intramuscular injection.
Biological: Trivalent Inactivated Vaccine (TIV)
Commercially available TIV, inactivated influenza vaccine (Split Virion) BP (Aventis Pasteur MSD, Lyon, France) was administered IM according to the manufacturer's dosing instructions (one 0.5-mL IM dose for adults).

  Eligibility

Ages Eligible for Study:   60 Years and older
Genders Eligible for Study:   Both
Accepts Healthy Volunteers:   Yes
Criteria

Inclusion Criteria:

  • who are aged at least 60 years or older at the time of enrollment;
  • who are determined by medical history, physical examination and clinical judgement to be eligible for this study;
  • who have provided written informed consent after the nature of the study has been explained;
  • who will be available for duration of the trial (from enrollment to November 30th, 2003);
  • who can be reached by study staff for the post-vaccination and weekly surveillance contacts [telephone, clinic or home visit].

Exclusion Criteria:

  • who are perceived to be unavailable or difficult to contact for evaluation or study visits during the study period;
  • who are a resident of a nursing home or long-term care facility or other institution receiving skilled or semi-skilled nursing care (refer to Influenza study specific manual). An ambulatory subject who is a resident of a retirement home or village is eligible for the trial;
  • with any signs of renal insufficiency requiring supportive therapy or progressive neurological disease. (Subjects with other stable pre-existing disease, defined as disease not requiring change in therapy or hospitalization within 12 weeks before receipt of study vaccination will be eligible).
  • with evidence of dementia or other severe cognitive impairment based on Mini Mental State Examination (MMSE) scores (refer to Influenza study specific manual);
  • with a known or suspected disease of the immune system or those receiving immunosuppressive therapy, including systemic corticosteroids; or cytotoxic agents;
  • who received any blood products, including immunoglobulin, in the period from six months prior to vaccination through to the conclusion of the study;
  • have an immunosuppressed or an immunocompromised individual living in the same household;
  • with a documented history of hypersensitivity to egg or egg protein or any other component of the CAIV-T or TIV vaccine;
  • who were administered any live virus vaccine within one month prior to vaccination or expected to receive another live virus vaccine within one month of vaccination in this study;
  • for whom there is intent to administer any other investigational vaccine or agent from one month prior to enrollment through to the conclusion of the study;
  • who received a dose of influenza treatment (commercial or investigational) one month prior to enrollment. The prophylactic use of influenza antivirals is not permitted.
  • who receive any influenza vaccine in the 6 months prior to enrollment, or intend to receive a non-study influenza vaccine after enrollment;
  • with any medical conditions that in the opinion of the investigator might interfere with interpretation of the study results; Note: A pregnant household member is not considered a contraindication to enrollment.
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its ClinicalTrials.gov identifier: NCT00192413

Locations
South Africa
Docnor House
Durban North, Dwazulu Natal, South Africa
Hazelmed Family Practice
Hazelwood, Pretoria, South Africa
Jansen van Rensburg
Amanzimtoti, South Africa
Christiaan Tertius de Villiers
Scottburgh South, South Africa
Sponsors and Collaborators
MedImmune LLC
Wyeth is now a wholly owned subsidiary of Pfizer
Investigators
Study Director: Robert Walker, MD MedImmune LLC
  More Information

Publications:
Responsible Party: Raburn Mallory, MD/ Sr Dir Clinical Development, MedImmune
ClinicalTrials.gov Identifier: NCT00192413     History of Changes
Other Study ID Numbers: D153-P516
Study First Received: September 13, 2005
Last Updated: March 13, 2012
Health Authority: United States: Food and Drug Administration
South Africa: Medicines Control Council

Additional relevant MeSH terms:
Influenza, Human
Orthomyxoviridae Infections
RNA Virus Infections
Virus Diseases
Respiratory Tract Infections
Respiratory Tract Diseases

ClinicalTrials.gov processed this record on August 28, 2014